Overexpression of CXCR4 has been associated with poor outcomes in patients with advanced cancer, including breast, head and neck, ovarian, and non-small cell lung cancer (NSCLC), among others [4, 9–14]. This evidence concerns the gene CXCR4 and non-small cell lung carcinoma.